MetaADEDB 2.0 @ LMMD
Brimonidine Tartrate
(QZHBYNSSDLTCRG-LREBCSMRSA-N)
Structure
SMILES
O[C@H]([C@H](C(=O)O)O)C(=O)O.Brc1c(ccc2c1nccn2)NC1=NCCN1
Molecular Formula:
C15H16BrN5O6
Molecular Weight:
442.221
Log P:
-0.5218
Hydrogen Bond Acceptor:
11
Hydrogen Bond Donor:
6
TPSA:
177.26
CAS Number(s):
59803-99-5; 70359-46-5
Synonym(s)
1.
Brimonidine Tartrate
2.
5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate
3.
5-bromo-6-(imidazolidinylideneamino)quinoxaline
4.
5-bromo-6-(imidazolin-2-ylamino)quinoxaline
5.
AGN 190342
6.
AGN-190342
7.
Alphagan
8.
Alphagan P
9.
Brimonidine
10.
Brimonidine Purite
11.
Brimonidine Tartrate (1:1)
12.
Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer
13.
Brimonidine Tartrate, (R-(R*,R*))-Isomer
14.
Bromoxidine
15.
Mirvaso
16.
Ratio-Brimonidine
17.
Sanrosa
18.
UK 14,304
19.
UK 14,304-18
20.
UK 14304
21.
UK 14308
22.
UK-14,304-18
23.
UK-14,308
24.
UK-14304
25.
AGN190342
26.
Ratio Brimonidine
27.
UK 14,304 18
28.
UK 14,30418
29.
UK 14,308
30.
UK14,30418
31.
UK14,308
32.
UK14304
External Link(s)
MeSHD000068438
PubChem Compound54405
KEGGdr:D02076
Therapeutic Target DatabaseD00ARM
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Eye irritationFAERS: 14
Canada Vigilance: 1		Canada Vigilance
US FAERS
2Eye painFAERS: 10US FAERS
3ConjunctivitisFAERS: 910877374CTD
US FAERS
4SomnolenceFAERS: 9US FAERS
5HypersensitivityFAERS: 8US FAERS
6PallorFAERS: 8US FAERS
7Accidental exposureFAERS: 6US FAERS
8BradycardiaFAERS: 6US FAERS
9LethargyFAERS: 6US FAERS
10PruritusFAERS: 6
Canada Vigilance: 1		Canada Vigilance
US FAERS
11Depressed Level of ConsciousnessFAERS: 5US FAERS
12DizzinessFAERS: 5US FAERS
13HeadacheFAERS: 5US FAERS
14Drug ineffectiveFAERS: 4
Canada Vigilance: 1		Canada Vigilance
US FAERS
15FatigueFAERS: 411641636CTD
US FAERS
16HypoventilationFAERS: 4US FAERS
17Product quality issueFAERS: 4US FAERS
18Visual ImpairmentFAERS: 4US FAERS
19Wrong drug administeredFAERS: 4US FAERS
20Chest PainFAERS: 3US FAERS
21DermatitisFAERS: 3US FAERS
22HypotensionFAERS: 3US FAERS
23IridocyclitisFAERS: 3US FAERS
24Product substitution issueFAERS: 3US FAERS
25Skin UlcerFAERS: 3US FAERS
26UveitisFAERS: 3US FAERS
27AstheniaFAERS: 2US FAERS
28Basal cell carcinomaFAERS: 2US FAERS
29Cardio-respiratory distressFAERS: 2US FAERS
30Eye InfectionFAERS: 2US FAERS
31Eyelid painFAERS: 2US FAERS
32Foreign body sensation in eyesFAERS: 2US FAERS
33MalaiseFAERS: 2US FAERS
34Medication ErrorFAERS: 2US FAERS
35No adverse eventFAERS: 2US FAERS
36Pharmaceutical product complaintFAERS: 2US FAERS
37PhotophobiaFAERS: 2US FAERS
38Product container issueFAERS: 2US FAERS
39Squamous cell carcinomaFAERS: 2US FAERS
40Toxicity to various agentsFAERS: 2US FAERS
41Unresponsive to stimuliFAERS: 2US FAERS
42AbasiaFAERS: 1US FAERS
43AgeusiaFAERS: 1US FAERS
44Anal discomfortFAERS: 1US FAERS
45Application site swellingFAERS: 1US FAERS
46ArthritisFAERS: 1US FAERS
47Atrial FibrillationFAERS: 1US FAERS
48Blood pressure immeasurableFAERS: 1US FAERS
49Burning sensationFAERS: 1US FAERS
50Cheyne-Stokes RespirationFAERS: 1US FAERS
51ConstipationFAERS: 1US FAERS
52DisorientationFAERS: 1US FAERS
53Drug dose omissionFAERS: 1US FAERS
54Drug toxicityFAERS: 1US FAERS
55DysacusisFAERS: 1US FAERS
56DysgeusiaFAERS: 1US FAERS
57DysphoniaFAERS: 1US FAERS
58Electrocardiogram abnormalFAERS: 1US FAERS
59Expired product administeredFAERS: 1US FAERS
60Eye RednessFAERS: 1US FAERS
61Eye allergyFAERS: 1US FAERS
62Eye laser surgeryFAERS: 1US FAERS
63Eyelid irritationFAERS: 1US FAERS
64Feeling abnormalFAERS: 1US FAERS
65FlushingFAERS: 1US FAERS
66Fontanelle depressedFAERS: 1US FAERS
67Glasgow coma scale abnormalFAERS: 1US FAERS
68Growth of eyelashesFAERS: 1US FAERS
69HyporeflexiaFAERS: 1US FAERS
70Impaired driving abilityFAERS: 1US FAERS
71InfectionFAERS: 1US FAERS
72Instillation site erythemaFAERS: 1US FAERS
73Instillation site irritationFAERS: 1US FAERS
74Instillation site painFAERS: 1US FAERS
75Instillation site reactionFAERS: 1US FAERS
76Intentional product use issueFAERS: 1US FAERS
77Loss of personal independence in daily activitiesFAERS: 1US FAERS
78Medication residue presentFAERS: 1US FAERS
79MoaningFAERS: 1US FAERS
80Musculoskeletal PainFAERS: 1US FAERS
81NauseaFAERS: 1US FAERS
82Nerve injuryFAERS: 1US FAERS
83NeuritisFAERS: 1US FAERS
84Ocular HypertensionFAERS: 111755835
12908569
17949534		CTD
US FAERS
85Oropharyngeal painFAERS: 1US FAERS
86Pelvic PainFAERS: 1US FAERS
87PoisoningFAERS: 1US FAERS
88Product administration errorFAERS: 1US FAERS
89Product contaminationFAERS: 1US FAERS
90Product dropper issueFAERS: 1US FAERS
91Product formulation issueFAERS: 1US FAERS
92Product leakageFAERS: 1US FAERS
93Product use complaintFAERS: 1US FAERS
94PseudophaeochromocytomaFAERS: 1US FAERS
95Respiratory DepressionFAERS: 1US FAERS
96Respiratory FailureFAERS: 1US FAERS
97RestlessnessFAERS: 1US FAERS
98SyncopeFAERS: 1US FAERS
99TachycardiaFAERS: 1US FAERS
100Therapeutic product ineffectiveFAERS: 1US FAERS
101Visual disturbanceFAERS: 1US FAERS
102Vitreous DetachmentFAERS: 1US FAERS
103VomitingFAERS: 1US FAERS
104Wrong technique in drug usage processFAERS: 1US FAERS
105Dermatitis, Allergic Contact10877374CTD
106Drug ineffective for unapproved indicationCanada Vigilance: 2Canada Vigilance
107Enteritis8982514CTD
108Eye Hemorrhage23820229CTD
109Glaucoma8970247
17949534
21979886		CTD
110Hyperemia10877374CTD
111Hyperglycemia8097719
17195055		CTD
112Ocular Hypotension15321024CTD
113Seizures6104728CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120238

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.